INT23105

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1990
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 5.17
Pain Relevance 0.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (MS4A1) plasma membrane (MS4A1)
Anatomy Link Frequency
B-cell 5
MS4A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 98.48 Very High Very High Very High
corticosteroid 4 92.72 High High
abatacept 2 89.16 High High
cytokine 3 88.48 High High
dexamethasone 1 78.16 Quite High
Arthritis 3 73.60 Quite High
Central nervous system 2 71.76 Quite High
tolerance 2 67.72 Quite High
Angina 2 65.44 Quite High
shoulder pain 2 64.32 Quite High
Disease Link Frequency Relevance Heat
Malignant Neoplastic Disease 2 98.80 Very High Very High Very High
Lymphatic System Cancer 19 98.00 Very High Very High Very High
Cancer 5 97.84 Very High Very High Very High
Systemic Lupus Erythematosus 61 96.32 Very High Very High Very High
Nephritis 6 95.92 Very High Very High Very High
Bullous Skin Disease 9 95.72 Very High Very High Very High
Progressive Multifocal Leukoencephalopathy 1 93.88 High High
Autoimmune Disease 3 88.56 High High
Mycobacterial Infection 2 87.96 High High
Pneumothorax 2 86.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Lymphomas of all cases were considered to have originated from B-cell lineage because their neoplastic cells expressed B1 (CD20) antigens.
Gene_expression (expressed) of CD20 in B-cell associated with lymphatic system cancer
1) Confidence 0.75 Published 1990 Journal Rinsho Ketsueki Section Abstract Doc Link 2381071 Disease Relevance 1.28 Pain Relevance 0.13
Another interesting therapeutic option is rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B-lymphocytes.
Gene_expression (found) of CD20 in B-lymphocytes associated with malignant neoplastic disease
2) Confidence 0.65 Published 2004 Journal Leuk. Lymphoma Section Abstract Doc Link 15512825 Disease Relevance 1.18 Pain Relevance 0.18
These new therapies are: (1) "B lymphocyte (BL)" inhibitors such as anti-CD20 monoclonal antibody, anti-CD22 monoclonal antibody, BlyS antagonists, tolerogens of pathogenic-antibody secreting LB (LJP 394) and edratide; (2) "Inhibitors of the costimulation" between antigen-presenting cells and T lymphocyte (TL) like monoclonal anti-CD40 ligand antibody or CTLA-4-Ig (abatacept); (3) "Cytokine antagonists" inhibiting key cytokines of SLE: interleukin-10, interferon-alpha, interleukin-6 and TNF.
Gene_expression (antibody) of CD20 in B lymphocyte associated with antagonist, abatacept, systemic lupus erythematosus and cytokine
3) Confidence 0.65 Published 2008 Journal Rev Med Interne Section Abstract Doc Link 18619716 Disease Relevance 0.43 Pain Relevance 0.27
B cell depletion via the anti-CD20 rituximab (Roche, Basel, Switzerland) was not successful in EXPLORER or LUNAR "generalized lupus" or nephritis-specific designed studies where all patients were given high doses of corticosteroids and immune suppressives as well [17,18].
Gene_expression (depletion) of anti-CD20 in B cell associated with corticosteroid, nephritis and systemic lupus erythematosus
4) Confidence 0.65 Published 2010 Journal BMC Med Section Body Doc Link PMC3009611 Disease Relevance 1.00 Pain Relevance 0.23
Lymphomas of all cases were considered to have originated from B-cell lineage because their neoplastic cells expressed B1 (CD20) antigens.
Gene_expression (expressed) of B1 in B-cell associated with lymphatic system cancer
5) Confidence 0.32 Published 1990 Journal Rinsho Ketsueki Section Abstract Doc Link 2381071 Disease Relevance 1.28 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox